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Maintenance of skeletal muscle mass 
during FOLFIRINOX is a favorable prognostic 
factor in pancreatic cancer patients
Dong Woo Shin1,2, Minseok Albert Kim3, Jong‑chan Lee1, Jaihwan Kim1 and Jin‑Hyeok Hwang1* 
Abstract 
Objective: The study aimed to investigate the effect of body composition changes during chemotherapy on clinical 
outcomes in patients with pancreatic cancer.
Results: In patients with locally advanced pancreatic cancer (LAPC), the cross‑sectional area of skeletal muscle 
(SM) and adipose tissue (AT) at the level of third lumbar vertebra was measured. The SM and AT ratios indicated the 
changes during chemotherapy. The patients were classified into three groups based on these ratios: group 1, ≥ 1.00; 
group 2, 0.85–0.99; group 3, < 0.85. The overall survival (OS) and surgical resection rates were estimated. Fifty‑eight 
patients with LAPC who received first‑line FOLFIRINOX were analyzed. Fifteen (25.9%) patients who underwent resec‑
tion showed maintained BMI, SM, and AT as compared to the patients who did not undergo resection. As the SM ratio 
decreased, the risk for death increased significantly. Further, the resection rate was significantly higher in patients with 
maintained SM compared to those with low SM ratio. On the contrary, the change in AT ratio was not associated with 
OS and resection rate; however, significant decrease in AT more than 15% showed poor clinical outcomes. Mainte‑
nance of SM during chemotherapy is a reliable prognostic factor indicating longer OS and higher resection rate.
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Introduction
Pancreatic cancer (PC) is the fourth leading cause of 
cancer-related deaths and has been projected to increase 
dramatically to become the second cause of cancer-
related deaths by 2030 in the United States (U.S.) [1, 2]. 
Patients with cancer are at an increased risk for muscle 
loss via two distinct mechanisms: sarcopenia, defined as 
the muscle atrophy that occurs with aging or immobil-
ity, and cachexia, defined as cytokine-mediated degrada-
tion of muscle and adipose tissue. Both wasting disorders 
are prevalent; among patients with cancer, 15–50% are 
sarcopenic and 25–80% are cachectic [3]. Cancer 
cachexia, which is characterized by weight loss, muscle 
wasting, and fat tissue depletion is commonly observed 
in patients with PC [4]. The loss of skeletal muscle (SM) 
and adipose tissue (AT) has been shown to adversely 
affect the patient survival in many cancers [5–7]. It has 
also been reported that sarcopenia at presentation is 
associated with an unfavorable prognosis in patients with 
both resectable and advanced PC [8–10]. The aforemen-
tioned reports suggest that a series of anthropometric 
changes during chemotherapy may provide an important 
information for prognosis in patients with PC. In most 
studies, the estimates of body compositions have been 
derived from the cross-sectional data, and not from the 
longitudinal data. At least one third of patients are diag-
nosed with locally advanced PC (LAPC) with extensive 
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LAPC primarily involves systemic chemotherapy, such 
as gemcitabine plus nab-paclitaxel or FOLFIRINOX [11, 
12]. Therefore, in the present study, we investigated the 
effect of the longitudinal changes in body composition 
during the first-line FOLFIRINOX chemotherapy on the 




Patients with LAPC who were treated with first-line 
FOLFIRINOX at Seoul National University Bundang 
Hospital (SNUBH) from April 2012 to June 2016 were 
enrolled. The current study was approved by the Institu-
tional Review Board of SNUBH (IRB approval number: 
B-1807–481-102).
The inclusion criteria for patients in this study were: 
(1) pathologically proven adenocarcinoma; (2) clini-
cally diagnosed with LAPC according to the Interna-
tional Study Group of Pancreatic Surgery criteria [13]; (3) 
received first-line FOLFIRINOX chemotherapy; (4) East-
ern Cooperative Oncology Group (ECOG) performance 
score of 0 or 1; and (5) availability of two computed 
tomography (CT) scans (one at the time of diagnosis and 
another after 6 months of FOLFIRINOX chemotherapy). 
The following patients were excluded from the study: (1) 
patients who did not receive FOLFIRINOX chemother-
apy; (2) patients with the recurrence of tumor; and (3) 
patients with poor performance status (ECOG ≥ 2).
Chemotherapy regimen/dose and follow‑up
The FOLFIRINOX regimen was administered to the 
patients at the following doses: oxaliplatin, 85  mg/m2; 
irinotecan, 180  mg/m2; leucovorin, 400  mg/m2; and 
fluorouracil, 400  mg/m2 given as a bolus, followed by 
2,400 mg/m2 given as a 46-h continuous infusion, every 
2 weeks. Modification of the dose was determined by the 
clinician based on toxicity and patient preference. Treat-
ment response was evaluated by CT scan after an aver-
age of three cycles of FOLFIRINOX chemotherapy using 
Response Evaluation Criteria in Solid Tumours (RECIST) 
criteria, version 1.1. The cumulative relative dose inten-
sity (cRDI, %), which considered the modification of dose 
intensity as well as cycle duration, was calculated using 
the RDI calculator at http:// www. hwang- lab. com.
Anthropometric measurements
Initial anthropometric values, including height and 
body weight, were retrieved from the medical records, 
and were used to calculate the body mass index (BMI, 
kg/m2). Serial CT scans at the time of diagnosis and 
after 6  months were used to quantify body composi-
tion, including the SM and AT areas. The boundaries of 
the body composition area were drawn manually on the 
serial cross-sectional CT images at the level of third lum-
bar vertebra (L3) and measurements were recorded using 
SliceOmatic software (v5.0; Tomovision, Canada) (Fig. 1). 
The anthropometric data were used to calculate the 
ratios by dividing the post-chemotherapy values by the 
pre-chemotherapy values. SM and AT ratios were classi-
fied into three groups as follows: group 1, ≥ 1.00; group 2, 
0.85–0.99; and group 3, < 0.85. The overall survival (OS), 
based on the SM and AT ratio groups, was estimated.
Statistical analyses
Categorical variables are presented as frequency and pro-
portion, and continuous variables as mean ± standard 
deviation. Continuous variables with normal distribu-
tion were analyzed using the Student’s t-test. Differences 
among the groups were tested using the chi-square test, 
or paired t-test. Survival time was estimated using the 
Kaplan–Meier survival curves and compared using the 
log-rank test. Hazard ratios (HRs) and 95% confidence 
intervals (95% CIs) for the univariate model of OS were 
calculated using the Cox regression analysis. A two-sided 
p-value of < 0.05 was considered statistically significant. 
The statistical analyses were performed using the IBM 




In the present study, initially 58 patients with LAPC were 
recruited from April 2012 to June 2016. The CT images 
before and after the administration of FOLFIRINOX 
chemotherapy were analyzed. After chemotherapy, 15 
(25.9%) patients underwent surgical resection.
Table  1 summarizes the demographic characteristics 
of the participants. The median age was 62.1 years, and 
34 (58.6%) patients were men. The median tumor size 
was 3.8 cm and the tumor was located in the head and/
or neck of the pancreas in 39 (67.2%) patients. At first 
presentation, the anthropometric data were as follows 
(mean ± standard deviation): BMI, 21.7 ± 2.9  kg/m2; SM 
area, 111.8 ± 24.9  cm2; and AT area, 202.1 ± 85.6  cm2. All 
variables measured at the time of diagnosis showed no 
statistically significant differences between the resection 
group and the non-resection group.
The patients received an average of 9 (range, 1–20) 
cycles of FOLFIRINOX chemotherapy. The resection 
group received more cycles of FOLFIRINOX chemother-
apy than the non-resection group, but the difference was 
not statistically significant (11 vs. 8 cycles; p = 0.193). The 
cRDI also did not show significant difference between 
the resection and non-resection groups (72.6% vs. 66.4%; 
p = 0.164).
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Anthropometric changes during the FOLFIRINOX 
chemotherapy
As shown in Table  2, the body compositions changed 
after the FOLFIRINOX chemotherapy. During the 6 
months of chemotherapy, BMI, SM area, and AT area 
decreased by 0.5 kg/m2, 12.6  cm2, and 24.1  cm2, respec-
tively. Among the 15 (25.9%) patients who underwent 
surgery after chemotherapy, these three indicators were 
maintained or increased (BMI was the same; SM area 
increased by an average of 0.3  cm2; AT area increased by 
3.2  cm2). However, these three anthropometric indices 
were significantly reduced in the unresected group (BMI 
decreased by 0.7 kg/m2; SM area decreased by 17.1  cm2; 
AT area decreased by 33.6  cm2).
Effect of anthropometric changes on the clinical outcome
Additional file  1: Table  S1 shows the effect of anthro-
pometric changes during FOLFIRINOX chemotherapy 
on survival and resectability. The median OS of all 58 
patients with LAPC was 16.1  months during a median 
duration of follow-up of 22.1 months. Regarding the SM 
ratio, 7 (12.1%), 31 (53.4%), and 20 (34.5%) patients were 
in group 1 (≥ 1.00), group 2 (0.85–0.99), and group 3 
(< 0.80), respectively. The median OS (95% CI) based on 
the SM ratios was as follows: group 1, not reached; group 
2, 19.1 (12.4–25.7) months; and group 3, 12.0 (9.0–15.0) 
months (Additional file  2: Figure S1a, Additional file  3: 
Figure S2a). As the SM ratio decreased, the risk of death 
increased significantly (group 1, reference; group 2, HR: 
4.871, 95% CI: 1.136–20.882; group 3, HR: 11.212, 95% 
CI: 2.527–49.738; p < 0.001). The likelihood of resection 
was significantly higher in patients with maintained SM 
as compared to those with low SM ratio (group 1, 71.4%; 
group 2, 32.3%; group 3, 0%; p < 0.001).
Based on the AT ratio, there were 16 (27.6%), 20 
(34.5%), and 22 (37.9%) patients in group 1 (≥ 1.00), 
group 2 (0.85–0.99), and group 3 (< 0.85), respectively. 
The median OS was not significantly different between 
group 1 (19.1 [11.5–26.7] months) and group 2 (17.5 
[7.1–27.9] months) (HR: 1.282, 95% CI: 0.576–2.856) 
(Additional file  2: Figure S1b, Additional file  3: Figure 
S2b). However, if the AT ratio decreased by more than 
15% (group 3), OS was significantly less (12.2 [11.1–13.3] 
months) (HR: 2.333, 95% CI: 1.067–5.103) than the group 
1 (reference). Moreover, no statistically significant dif-
ferences were observed in the resection rate among the 
Fig. 1 The quantification of body composition using computed tomography (CT) scan at the level of third lumbar vertebra (L3). a, b Cross‑sectional 
image at L3 level that measured the skeletal muscle mass and fat mass. c CT image before FOLFIRINOX chemotherapy. d CT image after 6 months 
of FOLFIRINOX chemotherapy. The purple color indicates skeletal muscle, yellow indicates visceral adipose tissue, and green indicates subcutaneous 
adipose tissue
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different groups based on AT ratio (group 1, 31.3%; group 
2, 35.0%; group 3, 13.6%; p = 0.243).
Discussion
The present study showed the longitudinal changes in 
body composition and the associations of these changes 
with clinical outcomes in patients with LAPC during 
the first-line FOLFIRINOX chemotherapy. The prin-
cipal findings of this study are: (i) the patients with 
Table 1 Baseline characteristics of the study population (n = 58)
The data are presented as mean ± standard deviation or n (%)
ECOG Eastern Cooperative Oncology Group, DM diabetes mellitus, CA19-9 carbohydrate antigen 19–9, CEA carcinoembryonic antigen, cRDI corrected relative dose 
intensity, BMI body mass index, SM skeletal muscle, AT adipose tissue
Patient characteristics Resection (n = 15) Non-resection (n = 43) Total (n = 58) p-value
Age (years) 60.0 ± 10.5 62.8 ± 8.4 62.1 ± 9.0 0.292
Male, n (%) 6 (40.0%) 28 (65.1%) 34 (58.6%) 0.163
ECOG score, n (%) 0.531
 0 8 (53.3%) 17 (39.5%) 25 (43.1%)
 1 7 (46.7%) 26 (60.5%) 33 (56.9%)
DM, n (%) 6 (40.0%) 20 (46.5%) 26 (44.8%) 0.892
Tumor size (cm) 3.7 ± 0.7 3.9 ± 1.5 3.8 ± 1.3 0.434
Tumor location, n (%) 0.542
 Head/neck 8 (53.3%) 31 (72.1%) 39 (67.2%)
 Body/tail 7(46.7%) 12 (27.9%) 19 (32.8%)
Vessel invasion, n (%) 0.266
 Artery 2 (13.3%) 9 (20.9%) 11 (19.0%)
 Vein 0 (0.0%) 5 (11.6%) 5 (8.6%)
 Both 13 (86.7%) 29 (67.4%) 42 (72.4%)
CA 19–9 (U/mL) 576 ± 1,220 963 ± 1,833 863 ± 1,695 0.452
CEA (ng/mL) 9.2 ± 19.3 5.4 ± 10.1 6.4 ± 13.0 0.469
FOLFIRINOX cycles [median (range)] 11 (2–16) 8 (1–20) 9 (1–20) 0.193
 ≥ 6 cycles 14 (93.3%) 33 (76.7%) 47 (81.0%) 0.304
cRDI (%) 72.6 ± 12.4 66.4 ± 15.2 68.0 ± 14.7 0.164
 ≥ 70% 8 (53.3%) 21 (48.8%) 29 (50.0%) 1.000
BMI (kg/m2) 22.7 ± 2.6 21.3 ± 3.0 21.7 ± 2.9 0.110
SM area  (cm2) 107.4 ± 26.6 113.3 ± 24.4 111.8 ± 24.9 0.435
AT area  (cm2) 211.4 ± 66.3 198.8 ± 91.9 202.1 ± 85.6 0.627
Table 2 Changes of body mass index, skeletal muscle area, and adipose tissue area during the first‑line FOLFIRINOX chemotherapy
The data are presented as mean ± standard deviation
BMI body mass index, SM skeletal muscle, AT adipose tissue
Variables Subgroups Before chemotherapy After chemotherapy p-value Difference 
(after-before)
Ratio (after/before)
BMI (kg/m2) Resection (n = 15) 22.7 ± 2.6 22.7 ± 2.8 0.935 0.0 ± 2.2 1.013 ± 0.104
No resection (n = 43) 21.3 ± 3.0 20.6 ± 3.2 0.013 − 0.7 ± 1.7 0.988 ± 0.078
Total (n = 58) 21.7 ± 2.9 21.2 ± 3.2 0.052 − 0.5 ± 1.8 0.997 ± 0.086
SM area  (cm2) Resection (n = 15) 107.4 ± 26.6 107.8 ± 27.3 0.889 0.3 ± 9.2 1.006 ± 0.099
No resection (n = 43) 113.3 ± 24.4 96.2 ± 22.9  < 0.001 − 17.1 ± 13.6 0.853 ± 0.116
Total (n = 58) 111.8 ± 24.9 99.2 ± 24.4  < 0.001 − 12.6 ± 14.7 0.911 ± 0.130
AT area  (cm2) Resection (n = 15) 211.4 ± 66.3 214.6 ± 63.4 0.832 3.2 ± 57.0 1.062 ± 0.353
No resection (n = 43) 198.8 ± 91.9 165.2 ± 83.4  < 0.001 − 33.6 ± 56.8 0.861 ± 0.253
Total (n = 58) 202.1 ± 85.6 178.0 ± 81.2 0.003 − 24.1 ± 58.7 0.889 ± 0.292
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well-maintained SM during chemotherapy were associ-
ated with higher resectability and longer OS than those 
with low SM ratio, even though cRDI was not differ-
ent. (ii) The AT change during chemotherapy was not 
correlated with clinical outcomes; however, significant 
decrease in AT ratio showed poor clinical outcomes.
The sarcopenia at the time of diagnosis has been 
reported to be an independent prognostic factor of 
reduced survival in PC patients as well as in several can-
cers [5–10, 14–19], the underlying mechanism that links 
sarcopenia with poor survival has not been fully eluci-
dated. A decrease in SM leads to aberrant energy home-
ostasis, impaired cell growth, insulin resistance, and 
immune dysfunction [20, 21]. In patients with PC, as well 
as nutritional deficiency, the insufficiency of pancreatic 
exocrine and endocrine functions, infection, and other 
metabolic factors can also contribute to the sarcopenia. 
The results of the present study showed that SM decrease 
during chemotherapy may be an important prognostic 
indicator for OS. SM decrease during chemotherapy may 
be a more important prognostic indicator than sarcope-
nia at the time of diagnosis. Many studies have reported 
that sarcopenic patients at the time of diagnosis have 
poor long-term outcomes [22–24]. The inability to main-
tain SM causes progressive functional impairment and a 
decreased quality of life, which in turn increases morbid-
ity and mortality [25, 26].
Further, the findings of our study suggest that AT loss 
was not significantly associated with prognosis. The sig-
nificant fat loss is associated with decreased survival 
in patients with PC, and this finding is consistent with 
the previously published data [27, 28]. Previous stud-
ies have shown that sarcopenia, sarcopenic obesity, and 
myosteatosis at the time of diagnosis are associated with 
decreased survival in patients with PC [29, 30]. However, 
owing to the complexity of PC, it is difficult to fully elu-
cidate the underlying mechanisms associated with AT 
reduction and poor clinical outcomes.
Furthermore, a study has implicated tumor Fn14 
(tumor necrosis factor receptor superfamily member 
12A; TNFRSF12A) as an inducer of cachexia in mice 
models, and it was shown that the antibodies against 
Fn14 prevented tumor-induced cachexia and extended 
lifespan without chemotherapy [31]. This suggests that 
regardless of chemotherapy, survival time can be pro-
longed if cachexia and sarcopenia are prevented. The 
efforts to maintain SM, including dietary or physical 
rehabilitation programs, concurrent administration of 
nutritional supplements, and/or drugs targeting chronic 
inflammation and cachexia may represent a critical adju-
vant strategy during chemotherapy [32].The determina-
tion of body compartments is an easy and quick tool that 
can be added without additional radiation exposure or 
cost. Anthropometric information can be easily applied 
in clinical setting with the potential to improve nutri-
tional care and chemotherapy dose calculation.
Conclusion
In conclusion, the anthropometric changes during the 
first-line FOLFIRINOX chemotherapy were associated 
with the clinical outcome in patients with LAPC. The 
findings of our study suggest that the patients with well-
maintained SM during chemotherapy have longer OS 
and higher resectability.
Limitations
The present study has some limitations. First, owing to its 
retrospective nature, we were unable to identify a causal 
relationship between sarcopenia and poor survival, and 
only revealed an association between them. Second, the 
information on standardized nutritional counseling dur-
ing chemotherapy was missing. Despite these limitations, 
this study has several strengths. First, the longitudinal 
assessment of serial anthropometric measurements was 
used throughout the course of chemotherapy in patients 
with PC. Progressive loss of SM during chemotherapy 
was more closely related to shorter OS than pretreatment 
sarcopenia. Because, SM volume decreases over time 
with the tumor progression, it should ideally be evaluated 
longitudinally. Second, body composition can be evalu-
ated by CT scan, which has the potential to become a fea-
sible and clinically relevant measure.
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